Merck Sharp + Dohme Corp.

John MacLean

Yusheng Xiong

Bheemashankar A Kulkarni

Clare London

Scott B Hoyt

Emma Louise Carswell

Paul David Ratcliffe

D Jonathan Bennett

Andrew John Cooke

Min K Park

Swapan Kumar Samanta

Jaiqiang Cai

Jiaqiang Cai

Jerry Andrew Taylor

Andrew Cooke

Rohit Saxena

Archana Gupta

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. 

Aldosterone synthase inhibitors

This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Pyrazolopyridyl compounds as aldosterone synthase inhibitors

This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Triazolopyridyl compounds as aldosterone synthase inhibitors

Growing community of inventors

Kilmarnock, United Kingdom

John MacLean